We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




NanoString Technology Modernizes Liposarcoma Diagnostics

By LabMedica International staff writers
Posted on 15 Feb 2021
A recently published study showed that a newer NanoString-based method could allow for more rapid and cost-efficient diagnosis of liposarcomas than the commonly used fluorescence in situ hybridization (FISH) method.

Liposarcoma is a rare type of cancer that arises in fat cells in soft tissue, such as that inside the thigh. More...
It is typically a large, bulky tumor, and tends to have multiple smaller satellites that extend beyond the main confines of the growth. Several types of liposarcoma exist. While some grow slowly with the cells remaining localized to one area of the body, other types grow very quickly and may metastasize.

In addition to FISH, which is a relatively expensive as well as labor- and equipment-intensive technology, immunohistochemistry (IHC) is often used to diagnose liposarcoma. However, IHC is felt to be inaccurate and hard to interpret.

To modernize the diagnosis of liposarcoma, investigators at the University of British Columbia (Vancouver, Canada) examined whether the newer NanoString-based technology (Seattle, WA, USA) could allow for more rapid and cost-efficient diagnosis of liposarcomas on standard formalin-fixed tissues through gene expression. For this study, they used large-scale transcriptome data from The Cancer Genome Atlas. The Cancer Genome Atlas is a project, begun in 2005, to catalog genetic mutations responsible for cancer, using genome sequencing and bioinformatics. The Cancer Genome Atlas applies high-throughput genome analysis techniques to improve diagnosis, treatment, and prevention of cancer through a better understanding of the genetic basis of this disease.

Data extracted from The Cancer Genome Atlas identified 20 genes, most from the 12q13-15 amplicon, that distinguished de-differentiated liposarcoma from other sarcomas and could be measured within a single NanoString assay. A machine learning model was subsequently developed to determine the probability that a given sample was positive for liposarcoma and was then applied to 45 retrospective cases to determine boundaries for positive and negative predictions. The effectiveness of the assay was validated on an independent set of 100 sarcoma samples (including 40 incident prospective cases), where histologic examination was considered insufficient for clinical diagnosis.

Results revealed that the NanoString assay had a 93% technical success rate, and an accuracy of 97.8% versus the FISH gold standard. Furthermore, results from the NanoString assay were available in 36 hours, whereas it required from one to two weeks to obtain FISH results.

"Liposarcomas are a type of malignant cancer that is difficult to diagnose because, even under a microscope, it is hard to differentiate liposarcomas from benign tumors or other types of cancer that need different treatments," said senior author Dr. Torsten Owen Nielsen, clinician-scientist in the department of pathology and laboratory medicine at the University of British Columbia. "Many liposarcomas look like their benign and relatively common counterparts, lipomas. Diagnostic delay and uncertainty cause severe stress for patients, and misdiagnosis can have many consequences including delayed or inadequate treatment or unnecessary surgical procedures and long-term postoperative follow up."

The liposarcoma-Nanostring study was published in the December 23, 2020 online edition of The Journal of Molecular Diagnosis.

Related Links:
University of British Columbia
NanoString



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.